Program Book - Confex

ACR/ARHP Poster Session B
1216. Baseline Predictors of Remission with Combination
Etanercept-Methotrexate Therapy in Moderately Active
Rheumatoid Arthritis: Interim Results of the PRESERVE
Trial. Josef Smolen 1 , Annette Szumski 2 , Lisa Marshall 2 and
Andrew S. Koenig 2 , 1 Medical University of Vienna and
Hietzing Hospital, Vienna, Austria, 2 Pfizer Inc., Collegeville,
PA
1217. Is Long-Term Etanercept Monotherapy Ever An Option in
a Patient with Moderate to Severe Rheumatoid Arthritis
(RA) Roy M. Fleischmann 1 , Michael H. Schiff 2 , Deborah
Wenkert 3 , Bojena Bitman 4 , Sandeep Chaudhari 5 , Jie Liu 6 ,
Grace S. Park 7 and Debra J. Zack 8 , 1 University of Texas
Southwestern Medical Center and Metroplex Clinical
Research Center, Dallas, TX, 2 Rheumatology Division,
University of Colorado, Denver, CO, 3 Amgen, Thousand Oaks,
CA, 4 Amgen Inc., South San Francisco, CA, 5 KForce Clinical
Research, Tampa, FL, 6 SimulStat Incorporated, San Diego,
CA, 7 Amgen Inc., Thousand Oaks, CA, 8 Amgen Inc, Thousand
Oaks, CA
1218. Efficacy and Safety of Certolizumab Pegol Plus
Methotrexate in Japanese Rheumatoid Arthritis Patients
with An Inadequate Response to Methotrexate. Kazuhiko
Yamamoto 1 , Tsutomu Takeuchi 2 , Hisashi Yamanaka 3 ,
Naoki Ishiguro 4 , Yoshiya Tanaka 5 , Katsumi Eguchi 6 ,
Akira Watanabe 7 , Hideki Origasa 8 , Toshiharu Shoji 9 ,
Yoshiharu Sakamaki 10 , Nobuyuki Miyasaka 11 and Takao
Koike 12 , 1 Graduate School of Medicine, The University
of Tokyo, Bunkyo-ku, Tokyo, Japan, 2 Keio University
School of Medicine, Shinjuku-ku, Tokyo, Japan, 3 Institute
of Rheumatology, Tokyo Women’s Medical University,
Shinjuku-ku, Tokyo, Japan, 4 Nagoya University, Graduate
School & Faculty of Medicine, Nagoya, Aichi, Japan,
5
University of Occupational & Environmental Health,
Kitakyushu, Fukuoka, Japan, 6 Sasebo City General Hospital,
Sasebo, Nagasaki, Japan, 7 Institute of Development, Aging
and Cancer, Tohoku University, Sendai, Miyagi, Japan,
8
University of Toyama School of Medicine, Toyama, Toyama,
Japan, 9 Otsuka Pharmaceutical Co., Ltd, Shinagawa-ku,
Tokyo, Japan, 10 UCB Inc, Chiyoda, Tokyo, Japan, 11 Graduate
School of Medicine and Dentistry, Tokyo Medical and Dental
University, Bunkyo-ku, Tokyo, Japan, 12 Sapporo Medical
Center NTT EC, Sapporo, Japan
1219. Integrated Safety Summary of Modified-Release
Prednisone and Immediate-Release Prednisone Comparing
Doses ≤5mg/Day Versus >5mg/Day. Frank Buttgereit 1 ,
Jacek Szechinski 2 , Gisela Doering 3 , Stephan Witte 4 , Christine
Knauer 4 , Amy Y. Grahn 5 , Kenneth G. Saag 6 and Rieke Alten 7 ,
1
Charité University Medicine, Berlin, Germany, 2 Wroclaw
Medical University, Wroclaw, Poland, 3 Merck KgaA,
Darmstadt, Germany, 4 Horizon Pharma GmbH, Mannheim,
Germany, 5 Horizon Pharma, Inc., Northbrook, IL, 6 University
of Alabama at Birmingham, Birmingham, AL, 7 Rheumatology
Schlossparkklinik, Berlin, Germany
1220. Efficacy and Safety of Certolizumab Pegol without
Methotrexate Co-Administration in Japanese Patients with
Active Rheumatoid Arthritis. Kazuhiko Yamamoto 1 , Tsutomu
Takeuchi 2 , Hisashi Yamanaka 3 , Naoki Ishiguro 4 , Yoshiya
Tanaka 5 , Katsumi Eguchi 6 , Akira Watanabe 7 , Hideki Origasa 8 ,
Koichi Iwai 9 , Yoshiharu Sakamaki 10 , Nobuyuki Miyasaka 11 and
Takao Koike 12 , 1 Graduate School of Medicine, The University
of Tokyo, Bunkyo-ku, Tokyo, Japan, 2 Keio University School
of Medicine, Tokyo, Japan, 3 Institute of Rheumatology,
Tokyo Women’s Medical University, Tokyo, Japan, 4 Nagoya
University, Graduate School & Faculty of Medicine, Nagoya,
Aichi, Japan, 5 University of Occupational and Environmental
Health, Japan, Kitakyushu, Fukuoka, Japan, 6 Sasebo City
General Hospital, Sasebo, Nagasaki, Japan, 7 Institute of
Development, Aging and Cancer, Tohoku University, Sendai,
Miyagi, Japan, 8 University of Toyama School of Medicine,
Toyama, Toyama, Japan, 9 Otsuka Pharmaceutical Co., Ltd,
Shinagawa-ku, Tokyo, Japan, 10 UCB Inc, Chiyoda, Tokyo,
Japan, 11 Tokyo Medical and Dental University, Tokyo, Japan,
12
Sapporo Medical Center NTT EC, Sapporo, Japan
1221. Dose Escalation Among Rheumatoid Arthritis Patients
Treated with Infliximab or Abatacept: Comparison in
Claims Data. Theodore Darkow 1 , Benjamin Chastek 2 , Lisa
Rosenblatt 1 , Digisha Trivedi 1 , Tony Hebden 1 , Henry Henk 2
and Fang Liu 2 , 1 Bristol-Myers Squibb, Plainsboro, NJ,
2
Innovus, an Optum Insight Company, Eden Prairie, MN
1222. The Effectiveness of Abatacept in a Large Rheumatoid
Arthritis Real World Practice: Changes in the HAQ
Over Time and Durability of Response. Janet E. Pope 1 ,
Emmanouil Rampakakis 2 , John S. Sampalis 2 and Olivier
Desjardins 3 , 1 St. Joseph’s Health Care, University of Western
Ontario, London, ON, 2 McGill University & JSS Medical
Research, Montreal, QC, 3 Bristol Myers Squibb Canada, St.
Laurent, QC
1223. Drug Survival and Long-Term Dose Comparison of
Etanercept and Infliximab in Rheumatoid Arthritis Patients.
Brian D. Hanna 1 and Alpesh Shah 2 , 1 McMaster University,
Ontario, Kitchener, ON, 2 Community Rheumatology Clinic,
Etobicoke, ON
1224. Remission According to Different Composite Disease
Activity Indices in Biologic-naïve Patients with Rheumatoid
Arthritis Treated with Abatacept or Infliximab Plus
Methotrexate. Josef S. Smolen 1 , Maxime Dougados 2 , Corine
Gaillez 3 , Coralie Poncet 4 , Manuela Le Bars 3 , Monica Mody 5
and Michael H. Schiff 6 , 1 Medical University of Vienna and
Hietzing Hospital, Vienna, Austria, 2 Hôpital Cochin, Paris,
France, 3 Bristol-Myers Squibb, Rueil Malmaison, France,
4
Docs International, Sévres, France, 5 Bristol-Myers Squibb,
Princeton, NJ, 6 University of Colorado, Denver, CO
1225. Pharmacokinetics of IV Abatacept in Systemic Lupus
Erythematosus Patients with Active Proliferative
Glomerulonephritis. Michael Tagen 1 , Blisse Vakkalagadda 1 ,
Neelima Thanneer 1 , Stephanie Meadows-Shropshire 1 ,
Martin Ullmann 1 , Robert Wong 1 , Richard Aranda 2 and Bindu
2011 Program Book 221